Dong Guo

List of Publications by Year
in descending order

53 papers	1,804 citations	279798 23 h-index	276875 41 g-index
54 all docs	54 docs citations	54 times ranked	2132 citing authors

#	Article	IF	Citations
1	Kinetics for Drug Discovery: an industry-driven effort to target drug residence time. Drug Discovery Today, 2017, 22, 896-911.	6.4	165
2	Functional efficacy of adenosine A_{2A} receptor agonists is positively correlated to their receptor residence time. British Journal of Pharmacology, 2012, 166, 1846-1859.	5.4	153
3	Controlling the Dissociation of Ligands from the Adenosine A_{2A} Receptor through Modulation of Salt Bridge Strength. Journal of Medicinal Chemistry, 2016, 59, 6470-6479.	6.4	151
4	Drugâ€Target Residence Timeâ€"A Case for G Proteinâ€Coupled Receptors. Medicinal Research Reviews, 2014, 34, 856-892.	10.5	145
5	Metformin induces osteoblastic differentiation of human induced pluripotent stem cellâ€derived mesenchymal stem cells. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, 437-446.	2.7	84
6	Molecular Basis of Ligand Dissociation from the Adenosine A_{2A} Receptor. Molecular Pharmacology, 2016, 89, 485-491.	2.3	72
7	Dual-Point Competition Association Assay: A Fast and High-Throughput Kinetic Screening Method for Assessing Ligand-Receptor Binding Kinetics. Journal of Biomolecular Screening, 2013, 18, 309-320.	2.6	65
8	Biased and Constitutive Signaling in the CC-chemokine Receptor CCR5 by Manipulating the Interface between Transmembrane Helices 6 and 7. Journal of Biological Chemistry, 2013, 288, 12511-12521.	3.4	59
9	Kinetic Aspects of the Interaction between Ligand and G Protein-Coupled Receptor: The Case of the Adenosine Receptors. Chemical Reviews, 2017, 117, 38-66.	47.7	51
10	Agonists for the Adenosine A₁ Receptor with Tunable Residence Time. A Case for Nonribose 4-Amino-6-aryl-5-cyano-2-thiopyrimidines. Journal of Medicinal Chemistry, 2014, 57, 3213-3222.	6.4	47
11	Binding Kinetics of ZM241385 Derivatives at the Human Adenosine A_{2A} Receptor. ChemMedChem, 2014, 9, 752-761.	3.2	45
12	GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A_{2B}receptor. FASEB Journal, 2011, 25, 632-643.	0.5	44
13	Defluorinative Alkylation of Trifluoromethylbenzimidazoles Enabled by Spin-Center Shift: A Synergistic Photocatalysis/Thiol Catalysis Process with CO₂^{â€¢â€“}. Organic Letters, 2022, 24, 4075-4080.	4.6	43
14	Drugâ€“Target Association Kinetics in Drug Discovery. Trends in Biochemical Sciences, 2019, 44, 861-871.	7.5	42
15	Ketamine induces hippocampal apoptosis through a mechanism associated with the caspase-1 dependent pyroptosis. Neuropharmacology, 2018, 128, 63-75.	4.1	40
16	The Role of Target Binding Kinetics in Drug Discovery. ChemMedChem, 2015, 10, 1793-1796.	3.2	37
17	5â€²-Substituted Amiloride Derivatives as Allosteric Modulators Binding in the Sodium Ion Pocket of the Adenosine A_{2A} Receptor. Journal of Medicinal Chemistry, 2016, 59, 4769-4777.	6.4	30
18	Novel Calcium Phosphate Cement with Metformin-Loaded Chitosan for Odontogenic Differentiation of Human Dental Pulp Cells. Stem Cells International, 2018, 2018, 1-10.	2.5	29

#	Article	IF	Citations
19	Structure-kinetics relationships of Capadenoson derivatives as adenosine A 1 receptor agonists. European Journal of Medicinal Chemistry, 2015, 101, 681-691.	5.5	28
20	Exploring Chemical Substructures Essential for hERG K⁺ Channel Blockade by Synthesis and Biological Evaluation of Dofetilide Analogues. ChemMedChem, 2009, 4, 1722-1732.	3.2	27
21	The Added Value of Assessing Ligandâ€“Receptor Binding Kinetics in Drug Discovery. ACS Medicinal Chemistry Letters, 2016, 7, 819-821.	2.8	27
22	Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2). Pharmaceutical Research, 2018, 35, 243.	3.5	24
23	Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women. American Journal of Obstetrics and Gynecology, 2021, 225, 85.e1-85.e11.	1.3	24
24	Application of a plasmin generation assay to define pharmacodynamic effects of tranexamic acid in women undergoing cesarean delivery. Journal of Thrombosis and Haemostasis, 2021, 19, 221-232.	3.8	23
25	Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity. Pharmaceutical Research, 2018, 35, 204.	3.5	22
26	Molecular mechanism of allosteric modulation at <scp>GPCRs</scp>: insight from a binding kinetics study at the human <scp>A</scp>₁ adenosine receptor. British Journal of Pharmacology, 2014, 171, 5295-5312.	5.4	20
27	Mass spectrometry-based ligand binding assays on adenosine A1 and A2A receptors. Purinergic Signalling, 2015, 11, 581-594.	2.2	20
28	Synthesis and Evaluation of Bile Acidâ€“Ribavirin Conjugates as Prodrugs to Target the Liver. Journal of Pharmaceutical Sciences, 2015, 104, 2864-2876.	3.3	19
29	Multidrug and toxin extrusion proteins mediate cellular transport of cadmium. Toxicology and Applied Pharmacology, 2017, 314, 55-62.	2.8	19
30	Functional organic cation transporters mediate osteogenic response to metformin in human umbilical cord mesenchymal stromal cells. Cytotherapy, 2018, 20, 650-659.	0.7	19
31	Equilibrium and kinetic selectivity profiling on the human adenosine receptors. Biochemical Pharmacology, 2016, 105, 34-41.	4.4	18
32	Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. Drug Metabolism and Disposition, 2016, 44, 489-494.	3.3	18
33	Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics. Molecular Pharmacology, 2017, 91, 25-38.	2.3	18
34	Long residence time adenosine A1 receptor agonists produce sustained wash-resistant antilipolytic effect in rat adipocytes. Biochemical Pharmacology, 2019, 164, 45-52.	4.4	17
35	mPGES-2 blockade antagonizes Î²-cell senescence to ameliorate diabetes by acting on NR4A1. Nature Metabolism, 2022, 4, 269-283.	11.9	16
36	Population pharmacokinetics and pharmacodynamics of Tranexamic acid in women undergoing caesarean delivery. British Journal of Clinical Pharmacology, 2021, 87, 3531-3541.	2.4	15

#	Article	IF	Citations
37	A twoâ€state model for the kinetics of competitive radioligand binding. British Journal of Pharmacology, 2018, 175, 1719-1730.	5.4	14
38	The LRP6 functional mutation rs2302685 contributes to individual susceptibility to alcoholic liver injury related to the Wnt/Î²-catenin-TCF1-CYP2E1 signaling pathway. Archives of Toxicology, 2019, 93, 1679-1695.	4.2	13
39	Cadmium exposure enhances organic cation transporter 2 trafficking to the kidney membrane and exacerbates cisplatin nephrotoxicity. Kidney International, 2020, 97, 765-777.	5.2	13
40	Benzodiazepine Derivatives as Potent Vasopressin V₂ Receptor Antagonists for the Treatment of Autosomal Dominant Kidney Disease. Journal of Medicinal Chemistry, 2022, 65, 9295-9311.	6.4	12
41	Disturbance of Mammary UDP-Glucuronosyltransferase Represses Estrogen Metabolism and Exacerbates Experimental Breast Cancer. Journal of Pharmaceutical Sciences, 2017, 106, 2152-2162.	3.3	11
42	Long Residence Time at the Vasopressin V₂ Receptor Translates into Superior Inhibitory Effects in Ex Vivo and In Vivo Models of Autosomal Dominant Polycystic Kidney Disease. Journal of Medicinal Chemistry, 2022, 65, 7717-7728.	6.4	11
43	Gating function of isoleucineâ€116 in <scp>TM</scp>â€3 (position <scp>III</scp>:16/3.40) for the activity state of the <scp>CC</scp>â€chemokine receptor 5 (<scp>CCR</scp>5). British Journal of Pharmacology, 2014, 171, 1566-1579.	5.4	10
44	Revisit ligand-receptor interaction at the human vasopressin V2 receptor: A kinetic perspective. European Journal of Pharmacology, 2020, 880, 173157.	3.5	8
45	Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy. Pharmacotherapy, 2021, 41, 205-211.	2.6	8
46	Indinavir Alters the Pharmacokinetics of Lamivudine Partially via Inhibition of Multidrug and Toxin Extrusion Protein 1 (MATE1). Pharmaceutical Research, 2018, 35, 14.	3.5	5
47	Pyrvinium Treatment Confers Hepatic Metabolic Benefits via Î²-Catenin Downregulation and AMPK Activation. Pharmaceutics, 2021, 13, 330.	4.5	5
48	Divergent Regulation of OCT and MATE Drug Transporters by Cadmium Exposure. Pharmaceutics, 2021, 13, 537.	4.5	4
49	Molecular Basis of Ligand Dissociation from G Protein-Coupled Receptors and Predicting Residence Time. Methods in Molecular Biology, 2018, 1705, 197-206.	0.9	3
50	<scp>PF</scp> â€06409577 inhibits renal cyst progression by concurrently inhibiting the <scp>mTOR</scp> pathway and <scp>CFTR</scp> channel activity. FEBS Open Bio, 0, , .	2.3	3
51	Metabolic Response to Olanzapine in Healthy Chinese Subjects with rs7093146 Polymorphism in Transcription Factor 7â€like 2 Gene (<scp>TCF</scp>7L2): A Prospective Study. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 601-609.	2.5	2
52	Lrp6 Genotype affects Individual Susceptibility to Nonalcoholic Fatty Liver Disease and Silibinin Therapeutic Response via Wnt/Î²-catenin-Cyp2e1 Signaling. International Journal of Biological Sciences, 2021, 17, 3936-3953.	6.4	2
53	Moxifloxacin derivatives with potential antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA). Current Topics in Medicinal Chemistry, 2021, 21, .	2.1	1